CD274 and non-small cell lung carcinoma: In the past decade, immune checkpoint inhibitors (ICI) targeting programmed death protein 1 (PD-1) and its ligand (PD-L1) or cytotoxic T lymphocyte antigen 4 (CTLA-4) have innovated the conventional therapy of NSCLC [2].